




FIG. 1

CD28 bispecific antibodies increase Luciferase production in the presence of primary T-cell stimulation and CD22 target expression.

FIG. 2A





FIG. 2B



CD28 bispecific antibodies increase IL-2 production in the presence of primary T-cell stimulation and CD22 target expression.

FIG. 3A






FIG. 3B




4/15



Combination of REGN5837 + Cemiplimab Enhances Max IL-2 release in the Presence of WSU-DLCL2 cells expressing PD-L1, most notably in the Presence of Belatacept.

FIG. 4


5/15



Combination of REGN5837 with Cemiplimab Enhances IL-2 Release above REGN5837 Treatment Alone in NALM6 Cells Engineered To Express PD-L1

FIG. 5A

6/15



Combination of REGN5837 with Cemiplimab Enhances IL-2 Release above REGN5837 Treatment Alone In RAJI Cells Engineered To Express PD-L1

FIG. 5B

Treatment of NSG Mice Bearing NALM-6-Luc Tumors with REGN5837 in the Presence of REGN1979 is Associated with Significant Tumor Suppression







FIG. 6




Cytotoxicity and T cell activation – Nalm6 Targets





Cytokine release from WSU-DLCL2 cytotoxicity assay (representative of 2 experiments)

FIG. 9



REGN5837 Enhances the Potency of REGN1979-Mediated Cytotoxicity, Cell-surface Expression of CD25, and T-Cell Proliferation in a Concentration-Dependent Manner

FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D






FIG. 11E



Fixed REGN5837
Concentration (M)
—▽— 1.00x10⁻⁷
—□— 1.67x10⁻⁸
—◇— 2.78x10⁻⁹
—◇— 4.63x10⁻¹⁰
—○— 7.72x10⁻¹¹
—+— 0

REGN5837 Enhances the Potency and Maximal Levels of REGN1979-Mediated Cytokine Release from Human T Cells in a Concentration-Dependent Manner in the Presence of WSU-DLCL2 B-Cell Lymphoma Cells




14/15


Treatment of NSG Mice Bearing WSU-DLCL2 Tumors with REGN5837 in the Presence of Sub-Efficacious Doses of REGN1979 is Associated with Significant Tumor Suppression

FIG. 13A

Average Tumor Growth
0.4 mg/kg REGN1979

**FIG. 13B**

Average Tumor Growth
4 mg/kg REGN1979



Treatment of NSG Mice Bearing WSU-DLCL2 Tumors with REGN5837 in the Presence of Sub-Efficacious Doses of REGN1979 is Associated with Significantly Greater Survival than REGN5837 or REGN1979 Monotherapy




FIG. 14